JP2011509916A - チアゾリジン誘導体およびその製造方法 - Google Patents

チアゾリジン誘導体およびその製造方法 Download PDF

Info

Publication number
JP2011509916A
JP2011509916A JP2009546026A JP2009546026A JP2011509916A JP 2011509916 A JP2011509916 A JP 2011509916A JP 2009546026 A JP2009546026 A JP 2009546026A JP 2009546026 A JP2009546026 A JP 2009546026A JP 2011509916 A JP2011509916 A JP 2011509916A
Authority
JP
Japan
Prior art keywords
thiazolidine
trifluorophenyl
amino
butanoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509916A5 (enExample
Inventor
キム・スンソ
アーン・ジンヘ
チョン・ヒェギョン
リー・サンダル
カン・ナムソク
キム・キヨン
カン・スンキュ
ジュン・ウォンホン
キム・スンギュ
キム・スンヨン
クウォン・ジェホン
ソーン・サンクウォン
シン・ミンキ
ハ・ニナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Yungjin Pharmaceutical Co Ltd
Kainos Medicine Inc
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Yungjin Pharmaceutical Co Ltd
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Yungjin Pharmaceutical Co Ltd, Kainos Medicine Inc filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of JP2011509916A publication Critical patent/JP2011509916A/ja
Publication of JP2011509916A5 publication Critical patent/JP2011509916A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009546026A 2007-01-16 2008-01-16 チアゾリジン誘導体およびその製造方法 Pending JP2011509916A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070004577A KR100848491B1 (ko) 2007-01-16 2007-01-16 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
PCT/IB2008/000773 WO2008087560A2 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof

Publications (2)

Publication Number Publication Date
JP2011509916A true JP2011509916A (ja) 2011-03-31
JP2011509916A5 JP2011509916A5 (enExample) 2011-05-12

Family

ID=39588017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546026A Pending JP2011509916A (ja) 2007-01-16 2008-01-16 チアゾリジン誘導体およびその製造方法

Country Status (11)

Country Link
US (1) US20100048570A1 (enExample)
EP (1) EP2118081A2 (enExample)
JP (1) JP2011509916A (enExample)
KR (2) KR100848491B1 (enExample)
CN (1) CN101720319A (enExample)
AU (1) AU2008206702A1 (enExample)
BR (1) BRPI0806592A2 (enExample)
CA (1) CA2712109A1 (enExample)
IL (1) IL199892A0 (enExample)
MX (1) MX2009007630A (enExample)
WO (1) WO2008087560A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2414906C2 (ru) 2005-02-16 2011-03-27 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы
WO2007078340A2 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
RU2642628C2 (ru) 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
US8039450B2 (en) 2008-03-06 2011-10-18 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US8461336B2 (en) * 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5475863B2 (ja) 2009-03-30 2014-04-16 ドン ア ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤及び中間体の改良された製造方法
MX2011010205A (es) 2009-03-30 2011-10-17 Dong A Pharm Co Ltd Procedimiento mejorado para la fabricacion de inhibidor de dipeptidil peptidasa-iv e intermediario.
US9440994B2 (en) 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
EP2555625B1 (en) * 2010-04-07 2018-11-14 GlaxoSmithKline LLC Process for preparing benzoxaboroles
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
RS62548B1 (sr) 2010-09-07 2021-12-31 Anacor Pharmaceuticals Inc Derivati benzoksaborola za lečenje bakterijskih infekcija
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103122009B (zh) * 2013-01-09 2015-11-25 江苏吉贝尔药业股份有限公司 两种用于合成他卡西醇支链的重要中间体化合物
CN103012463B (zh) * 2013-01-17 2016-02-10 南京理工大学 (s)-3-甲基-2-(叔丁基二甲基硅氧基)-1-溴丁烷的合成方法
JP6499175B2 (ja) 2013-08-09 2019-04-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 三環式ベンゾキサボロール化合物及びその使用
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509921A (ja) * 1993-12-03 1997-10-07 フェーリング ベスローテン フェンノートシャップ 酵素インヒビター
JP2002363157A (ja) * 2001-05-15 2002-12-18 Lab Servier 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物
JP2003535034A (ja) * 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
JP2004535433A (ja) * 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
JP2005523248A (ja) * 2001-12-26 2005-08-04 ギルフォード、ファーマスーティカルズ ジペプチジルペプチダーゼｉｖの阻害剤
JP2006509839A (ja) * 2002-11-07 2006-03-23 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
JP2006510630A (ja) * 2002-12-04 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
WO2006040625A1 (en) * 2004-10-12 2006-04-20 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2790895A (en) * 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509921A (ja) * 1993-12-03 1997-10-07 フェーリング ベスローテン フェンノートシャップ 酵素インヒビター
JP2003535034A (ja) * 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
JP2002363157A (ja) * 2001-05-15 2002-12-18 Lab Servier 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物
JP2004535433A (ja) * 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
JP2005523248A (ja) * 2001-12-26 2005-08-04 ギルフォード、ファーマスーティカルズ ジペプチジルペプチダーゼｉｖの阻害剤
JP2006509839A (ja) * 2002-11-07 2006-03-23 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
JP2006510630A (ja) * 2002-12-04 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
WO2006040625A1 (en) * 2004-10-12 2006-04-20 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5009020286; ＥＤＭＯＮＤＳＯＮ　Ｓ　Ｄ: ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ Ｖ１４　Ｎ２０, 20041018, Ｐ５１５１-５１５５ *
JPN5009020287; Ｊ．ＸＵ: ＢＩＯＯＲＧ．ＭＥＤ．ＣＨＥＭ．ＬＥＴＴ． Ｖ１４, 2004, Ｐ４７５９-４７６２ *
JPN6013009058; Ｄｏｒｅｅｎ　Ｍ．　Ａｓｈｗｏｒｔｈ　ｅｔ　ａｌ: Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ　Ｌｅｔｔｅｒｓ Ｖｏｌ．６（２２）, 1996, ｐ．２７４５-２７４８ *

Also Published As

Publication number Publication date
CN101720319A (zh) 2010-06-02
KR100848491B1 (ko) 2008-07-28
MX2009007630A (es) 2010-02-15
US20100048570A1 (en) 2010-02-25
WO2008087560A2 (en) 2008-07-24
WO2008087560A3 (en) 2008-09-12
KR20100094337A (ko) 2010-08-26
BRPI0806592A2 (pt) 2014-05-06
IL199892A0 (en) 2010-04-15
CA2712109A1 (en) 2008-07-24
EP2118081A2 (en) 2009-11-18
AU2008206702A1 (en) 2008-07-24
WO2008087560A9 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
JP2011509916A (ja) チアゾリジン誘導体およびその製造方法
JP3022951B2 (ja) アロイル−ピペリジン誘導体
JP2023011677A (ja) γ－ヒドロキシ酪酸（ＧＨＢ）のプロドラッグ、その組成物および使用
DE60216094T2 (de) Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)
EP0807111B1 (fr) Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2291966T3 (es) Inhibidores de dpp-iv.
CA2731789C (fr) Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique
CN1274288A (zh) 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
SK282753B6 (sk) Deriváty 4-hydroxyfenylalkánových kyselín, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
HUT76637A (en) Bezoxazoles and pyridine derivatives, pharmaceutical compositions containing them, process for producing them and their use and the intermediates of the compounds
US20170204065A1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
MX2008011641A (es) Nueva forma g cristalina de (5s)-5-[4-(5-cloro-piridin-2-iloxi)-pi peridin-1-sulfonil-metil]-5-metil-imidazolidin-2, 4-diona (i) y sus intermediarios.
JP2009167215A (ja) 新規ジアリールアルケン誘導体及び新規ジアリールアルカン誘導体
BE1009571A3 (fr) Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant.
CH655309A5 (fr) Composes d'azetidine.
FR2842523A1 (fr) Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CA2498149A1 (en) 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
TW201319036A (zh) 苯基衍生物
WO1998021185A1 (en) Arylureas or arylmethylcarbamoyl derivatives
US8119673B2 (en) Compounds 148
EP1908466B1 (en) Substituted propanamide derivative and pharmaceutical composition containing the same
JP2001011037A (ja) シクロアルカンカルボン酸アミド誘導体
US6903111B2 (en) Isoquinuclidine derivative process for producing the same, and medicinal composition containing the same
AU2008267287A1 (en) N5-(2-ethoxyethyl)-N3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
WO2014164844A1 (en) Cathepsin inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130730